Developer docs
API playgroundTry for free, no card

Search company profiles

Bioscreen

Full company profile

uuid000gykq

Namestring
Bioscreen
Legal namestring
Bioscreen Ltd Pty
Company typeenum
Private
Founded yearint
1982
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersYarraville, Australia
HQ citystring
Yarraville
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gut microbiota testing, faecal microbial analysis, MALDI-TOF identification, live bacteria culturing, duodenal aspirate testing
Industry3 codes
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Microbiology Laboratory Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Services
TypeOne Time License
Description

Bioscreen generates revenue through one-time test fees for the Faecal Microbial Analysis (FMA) test and Duodenal Aspirate test. Payment is required in advance of service provision. Tests are paid via Mastercard, Visa, Cheque, Money Order, or Cash. The company also offers paid consultations with Dr. Butt for practitioners at AUD $100 per session.

bioscreenmedical.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Supply Chain
Pricing details2 tiers
1Faecal Microbial Analysis (FMA) Test - fee not publicly disclosed
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

FMA test fee is quote-based; requires test request form from registered practitioner. Turnaround time is 2 weeks from sample receipt.

bioscreenmedical.com
2Practitioner Consultation - AUD $100
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Consultation with Dr. Butt to discuss test results incurs a fee of AUD $100.

bioscreenmedical.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Bioscreen is a specialist microbiological laboratory that analyses gut microbiota for healthcare practitioners and their patients. The company's core offering is the Faecal Microbial Analysis (FMA) Test, which uses classical culture methodology (culturomics) combined with MALDI-TOF mass spectrometry to culture, quantify, and identify live bacteria from faecal samples, providing quantitative data on commensal gut bacteria. Bioscreen also offers a Duodenal Aspirate Test for analysis of the upper small intestine microbiota.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Bioscreen is a specialist microbiological laboratory offering two diagnostic testing products. The primary product is the Faecal Microbial Analysis (FMA) Test, which analyzes gut microbiota using classical culture and MALDI-TOF mass spectrometry to identify and quantify live bacteria from faecal samples. The secondary product is the Duodenal Aspirate Test, which analyzes the microbiota of the upper small intestine. Both products are supported by a sample collection kit that patients use at home to collect and return samples via prepaid shipping. The company positions its testing as distinct from DNA-based competitors by focusing on culturing live bacteria, considered the 'Gold Standard' in microbiological testing.

Product and service2 records
1Faecal Microbial Analysis (FMA) Test
CategoryDiagnostic Laboratory Testing
Description

Comprehensive analysis of gut microbiota from the large intestinal tract using classical culture techniques and MALDI-TOF mass spectrometry for identification. The test cultures, quantifies, and identifies live bacteria including aerobic organisms (coliforms, Enterococcus, Streptococcus), anaerobic bacteria (Bacteroides, Eubacterium, Bifidobacterium, Lactobacillus, Clostridium), and yeasts (Candida, Saccharomyces). It is offered to patients referred by registered healthcare practitioners and provides actionable clinical information for treatment decisions including dietary modification, probiotic protocols, and antimicrobial therapy.

2Duodenal Aspirate Test
CategoryDiagnostic Laboratory Testing
Description

Analysis of the microbiota of the upper small intestine (duodenum), providing complementary testing to the FMA test for assessment of small intestinal bacterial overgrowth and upper gut microbiota composition.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Australian gut microbiome testing company using DNA sequencing to profile microbial communities from faecal samples. Direct competitor to Bioscreen in the Australian gut-microbiome diagnostic market, with overlapping practitioner referral channels and similar patient indications, but using a sequencing rather than culturing methodology.

TypeDirect peer
Description

US-based direct-to-consumer gut microbiome testing company using metatranscriptomic sequencing plus AI analysis. Competes with Bioscreen on the same underlying use case (gut health testing) but serves customers globally via e-commerce rather than practitioner-mediated sales.

TypeDirect peer
Description

US clinical laboratory offering GI pathogen and microbiome profiling for healthcare practitioners, including qPCR-based stool testing. Comparable to Bioscreen in serving functional and integrative medicine practitioners with stool-based diagnostics, though with a broader menu and DNA-based methods.

TypeBroad incumbent
Description

Established specialty clinical laboratory offering a wide portfolio of stool, hormone, and nutritional diagnostics through healthcare providers. Larger incumbent with overlapping GI testing menu including CDSA stool parasitology, comparable to Bioscreen's practitioner-mediated lab services but with much broader test catalog and US footprint.

TypeBroad incumbent
Description

US specialty lab providing stool microbiology, toxic metals, and hormone testing to integrative and functional medicine practitioners. Comparable to Bioscreen in targeting the same practitioner channel for gut health diagnostics, but operates as an established incumbent with a much broader specialty testing menu.

TypeRegional player
Description

Australia-based gut microbiome testing company using 16S rRNA sequencing for consumers and clinicians. Regional competitor to Bioscreen in the Australian market, overlapping on practitioner-referred gut testing but with a sequencing rather than culturing methodology.

TypeBroad incumbent
Description

US-based health and wellness company offering microbiome testing alongside supplements, using shotgun metagenomic sequencing. Comparable to Bioscreen in providing gut microbiome insights to consumers and practitioners, but as part of a much broader nutritional supplement business.

8BioGaia
TypeOthers
Description

Swedish probiotic company developing Lactobacillus-based products with clinical evidence in gut and oral health. Adjacent to Bioscreen's practitioner channel rather than a direct competitor, as BioGaia supplies probiotics rather than diagnostic testing.

TypeEmerging player
Description

Microbiome genomics company offering sequencing-based characterization of microbial communities for clinical and industrial customers. Comparable to Bioscreen in microbiome analytical services but addresses research, industrial, and clinical customers with sequencing platforms rather than culturomics.

10Invivo Clinical
TypeDirect peer
Description

UK-based clinical laboratory offering microbiome and functional medicine testing through healthcare practitioners. Comparable to Bioscreen in practitioner-mediated gut health diagnostics with overlapping indications (IBS, SIBO, dysbiosis), though primarily serving UK/European markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioscreen

Clinical Microbiology Laboratory Servicesbioscreenmedical.com

Bioscreen firmographics

Firmographics
Name
Bioscreen
Legal name
Bioscreen Ltd Pty
Website
https://bioscreenmedical.com
Company type
Private
Founded year
1982
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Bioscreen industry classification

Industry
Product category
Clinical Microbiology Laboratory Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Gut microbiota testing
  • Faecal microbial analysis
  • MALDI-TOF identification
  • Live bacteria culturing
  • Duodenal aspirate testing

Where Bioscreen is headquartered

Location

Headquarters

HQ city
Yarraville
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Bioscreen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain

Revenue model

  1. Diagnostic Testing Services: Bioscreen generates revenue through one-time test fees for the Faecal Microbial Analysis (FMA) test and Duodenal Aspirate test. Payment is required in advance of service provision. Tests are paid via Mastercard, Visa, Cheque, Money Order, or Cash. The company also offers paid consultations with Dr. Butt for practitioners at AUD $100 per session.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goFaecal Microbial Analysis (FMA) Test - fee not publicly disclosed
One time/ perpetual licensePay-as-you-goPractitioner Consultation - AUD $100

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Bioscreen product offering

Product offering

Core offering

Bioscreen is a specialist microbiological laboratory that analyses gut microbiota for healthcare practitioners and their patients. The company's core offering is the Faecal Microbial Analysis (FMA) Test, which uses classical culture methodology (culturomics) combined with MALDI-TOF mass spectrometry to culture, quantify, and identify live bacteria from faecal samples, providing quantitative data on commensal gut bacteria. Bioscreen also offers a Duodenal Aspirate Test for analysis of the upper small intestine microbiota.

Product overview

Bioscreen is a specialist microbiological laboratory offering two diagnostic testing products. The primary product is the Faecal Microbial Analysis (FMA) Test, which analyzes gut microbiota using classical culture and MALDI-TOF mass spectrometry to identify and quantify live bacteria from faecal samples. The secondary product is the Duodenal Aspirate Test, which analyzes the microbiota of the upper small intestine. Both products are supported by a sample collection kit that patients use at home to collect and return samples via prepaid shipping. The company positions its testing as distinct from DNA-based competitors by focusing on culturing live bacteria, considered the 'Gold Standard' in microbiological testing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Faecal Microbial Analysis (FMA) Test Comprehensive analysis of gut microbiota from the large intestinal tract using classical culture techniques and MALDI-TOF mass spectrometry for identification. The test cultures, quantifies, and identifies live bacteria including aerobic organisms (coliforms, Enterococcus, Streptococcus), anaerobic bacteria (Bacteroides, Eubacterium, Bifidobacterium, Lactobacillus, Clostridium), and yeasts (Candida, Saccharomyces). It is offered to patients referred by registered healthcare practitioners and provides actionable clinical information for treatment decisions including dietary modification, probiotic protocols, and antimicrobial therapy.
  • Duodenal Aspirate Test Analysis of the microbiota of the upper small intestine (duodenum), providing complementary testing to the FMA test for assessment of small intestinal bacterial overgrowth and upper gut microbiota composition.

Companies that use Bioscreen

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Bioscreen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Bioscreen partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Bioscreen competitors and assessment

Company assessment

Direct peers

  • Microba: Australian gut microbiome testing company using DNA sequencing to profile microbial communities from faecal samples. Direct competitor to Bioscreen in the Australian gut-microbiome diagnostic market, with overlapping practitioner referral channels and similar patient indications, but using a sequencing rather than culturing methodology.
  • Viome: US-based direct-to-consumer gut microbiome testing company using metatranscriptomic sequencing plus AI analysis. Competes with Bioscreen on the same underlying use case (gut health testing) but serves customers globally via e-commerce rather than practitioner-mediated sales.
  • Diagnostic Solutions Laboratory: US clinical laboratory offering GI pathogen and microbiome profiling for healthcare practitioners, including qPCR-based stool testing. Comparable to Bioscreen in serving functional and integrative medicine practitioners with stool-based diagnostics, though with a broader menu and DNA-based methods.
  • Invivo Clinical: UK-based clinical laboratory offering microbiome and functional medicine testing through healthcare practitioners. Comparable to Bioscreen in practitioner-mediated gut health diagnostics with overlapping indications (IBS, SIBO, dysbiosis), though primarily serving UK/European markets.

Broad incumbents

  • Genova Diagnostics: Established specialty clinical laboratory offering a wide portfolio of stool, hormone, and nutritional diagnostics through healthcare providers. Larger incumbent with overlapping GI testing menu including CDSA stool parasitology, comparable to Bioscreen's practitioner-mediated lab services but with much broader test catalog and US footprint.
  • Doctor's Data: US specialty lab providing stool microbiology, toxic metals, and hormone testing to integrative and functional medicine practitioners. Comparable to Bioscreen in targeting the same practitioner channel for gut health diagnostics, but operates as an established incumbent with a much broader specialty testing menu.
  • Thorne (OneGut / Microbiome): US-based health and wellness company offering microbiome testing alongside supplements, using shotgun metagenomic sequencing. Comparable to Bioscreen in providing gut microbiome insights to consumers and practitioners, but as part of a much broader nutritional supplement business.

Regional players

  • Smart DNA: Australia-based gut microbiome testing company using 16S rRNA sequencing for consumers and clinicians. Regional competitor to Bioscreen in the Australian market, overlapping on practitioner-referred gut testing but with a sequencing rather than culturing methodology.

Others

  • BioGaia: Swedish probiotic company developing Lactobacillus-based products with clinical evidence in gut and oral health. Adjacent to Bioscreen's practitioner channel rather than a direct competitor, as BioGaia supplies probiotics rather than diagnostic testing.

Emerging players

  • CosmosID: Microbiome genomics company offering sequencing-based characterization of microbial communities for clinical and industrial customers. Comparable to Bioscreen in microbiome analytical services but addresses research, industrial, and clinical customers with sequencing platforms rather than culturomics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Bioscreen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioscreen leadership team

Management profile

Number of profiles

Profiles3 records

Bioscreen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioscreen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioscreen

What does Bioscreen do?

Bioscreen is a specialist microbiological laboratory that analyses gut microbiota for healthcare practitioners and their patients. The company's core offering is the Faecal Microbial Analysis (FMA) Test, which uses classical culture methodology (culturomics) combined with MALDI-TOF mass spectrometry to culture, quantify, and identify live bacteria from faecal samples, providing quantitative data on commensal gut bacteria. Bioscreen also offers a Duodenal Aspirate Test for analysis of the upper small intestine microbiota.

Is Bioscreen a public or private company?

Bioscreen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Bioscreen founded?

Bioscreen was founded in 1982. It employs 1 to 10 people.

Where is Bioscreen based?

Bioscreen is headquartered in Yarraville, Australia, in the Oceania region.

How does Bioscreen make money?

One revenue line is on record: diagnostic Testing Services.

Who are Bioscreen's main competitors?

Direct peers on record are Microba, Viome, Diagnostic Solutions Laboratory and Invivo Clinical. Broad incumbents are Genova Diagnostics, Doctor's Data and Thorne (OneGut / Microbiome). Smart DNA is listed as a regional player. BioGaia is listed as an others. CosmosID is listed as an emerging player.

Does Bioscreen have an API?

No public API is recorded for Bioscreen.

What industry is Bioscreen in?

Bioscreen's product category is Clinical Microbiology Laboratory Services. Its primary akta.pro industry code is HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal), with a secondary code of HLAFAMAD, Microbiology & Infectious Disease Testing Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales